THE TAPE
BIIB · Biotechnology · $37.2B

Biogen Inc. Common Stock

$251.65▼ −0.69%
Last close
Relative strength
89RS
of 99, against every stock▲ +1 on the month
Powering up
Developing
+6.8%
six months against Biotechnology
52-week range
−3.6%
from the high
$160.36$261.00
Setup
vcpclimbing
+14.5%
against the pivot at $219.72
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +11% on a year ago
11/16 O 255.25 H 255.42 L 250.65 Vol 839.8K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS89
vs pivot+14.53%
Tightening1.49×
Dry-up1.51×
Up/down vol0.06
From high4%
climbing8 of 9checks
Previous breakout stopped out ▼ −8.18% in May
Powering up
Support and resistance
Support below
$240.57
-4.4% · tested 4× · last 6 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 7.2 weeks and fell 15% from its ceiling at its deepest. The pivot is $219.72, and the stock closed 14.5% above that pivot. Its relative strength rating is 89.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+5.1%
Three months against its industry
+26.3%
Six months against its industry
+6.8%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Also on
Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 2.7% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$10.3B
+10.6% year on year
Operating margin
—
Net margin
3.4%
Free cash flow
$2.1B
5.6% of market cap
Price to sales
3.61×
Price to earnings
107.0×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 28
Key takeaway
A mixed quarter: the numbers do not agree.
Revenue
$2.8B
+2.5% QoQ · +10.6% YoY
Gross margin
—
Net income
−$20.6M
Loss
Free cash flow
$600.4M
Cash generating

What the numbers say

  • Revenue +10.6% year over year, +2.5% on the quarter
  • Weak: Net loss $21M
  • Good: Cash generating: operating cash flow $641M, free cash flow $600M
  • Weak: Net debt $5.99B · cash $1.30B
Revenue by quarter
Free cash flow
Net income
shares +0.5% in a year · net debt $6.0B
Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is operating profit: net loss $21M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 3 of 46 tracked funds at the end of Q3 2026.

Last quarter: 2 bought new, 1 trimmed, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-10-29
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-29
above 20d & 50d on 2.0x volume at 244.05
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Earnings comingEvent · 2026-10-27
reports 2026-10-28 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
GappedTape · 2026-10-22
+5.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-09-19
10.4 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
2
$239,750 total

Sold: Minor Lloyd.

Not counted above: 14 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-30 Grogan Jane · Head of Researchoption exercise695
2026-10-30 Grogan Jane · Head of Researchwithheld for tax345$87,499
2026-10-02 Godbout Sean · Chief Accounting Officeroption exercise27
2026-10-02 Godbout Sean · Chief Accounting Officerwithheld for tax8$1,759
2026-08-04 Minor Lloyd · Directorsell593$119,169
2026-08-03 Minor Lloyd · Directorsell593$120,581
2026-06-09 HAWKINS WILLIAM A · Directoraward1,505
2026-06-09 SHERWIN STEPHEN A · Directoraward1,505

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

8 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy4
Buy21
Hold10
Sell1
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
7w · 15%

The most recent of 5 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Biogen Inc. Common Stock (BIIB) — The Tape